Mereo BioPharma (MREO) Notes Payables (2017 - 2024)

Mereo BioPharma (MREO) has reported Notes Payables for 7 consecutive years, with $5.5 million the latest figure, recorded in Q4 2024.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $5.5 million in Q4 2024; TTM through Dec 2024 was $5.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $5.5 million, changed N/A from the prior year.
• Notes Payables was $5.5 million for Q4 2024 at Mereo BioPharma, roughly flat from $5.6 million in the prior quarter.
• Over five years, Notes Payables peaked at $16.5 million in Q2 2020 and troughed at $4.6 million in Q1 2024.
• A 4-year average of $7.9 million and a median of $5.5 million in 2024 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables surged 59.71% in 2020 and retreated 5.86% in 2024, its largest moves.
• Over 4 years, Notes Payables stood at $16.5 million in 2020, then retreated by 21.0% to $13.0 million in 2022, then tumbled by 59.71% to $5.2 million in 2023, then advanced by 5.67% to $5.5 million in 2024.
• The last three Notes Payables figures came in at $5.5 million (Q4 2024), $5.6 million (Q3 2024), and $4.9 million (Q2 2024), per Business Quant data.